InvestSMART

Argenica Therapeutics Limited (ASX:AGN)

ALERT: Price-sensitive ASX Announcement for AGN
Current share price for AGN : $0.125 -0.52 (-80.62%)+
Announcement
Release
3 Sep 2025 9:34AM
Price at Release
$0.645
Full Release
download
Summary
Argenica Therapeutics Limited announced the topline results of their Phase 2 trial of ARG-007 in acute ischemic stroke (AIS) patients. The trial confirmed that ARG-007 is safe and well-tolerated, with no statistically significant difference in adverse events compared to placebo. While the overall treatment effect on infarct volume reduction was not significant, a predefined subgroup of patients with slow collateral blood flow, comprising 30% of trial participants, showed a promising 15% reduction in infarct volume. This efficacy signal aligns with the company's hypothesis that these 'rapid progressors' could benefit most from ARG-007's neuroprotective potential. The positive safety data and targeted efficacy findings provide a foundation for future trials focusing on at-risk patient subgroups, enhancing the potential for ARG-007 to address a critical unmet need in stroke treatment.
Key Points
  • ARG-007 found to be safe and well tolerated in AIS patients.
  • No significant drug-to-drug interactions with clot dissolving drugs.
  • Overall efficacy on infarct volume reduction not significant.
  • Efficacy signal observed in patients with slow collateral blood flow.
  • 15% infarct volume reduction in 'rapid progressors'.
  • Future trials to focus on at-risk patient subgroups.
  • Support for ARG-007's neuroprotective potential.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should refer to the full announcement here for further information.